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Summary
Background Dupilumab blocks the shared receptor component for interleukin (IL)-4
and IL-13. It is approved in the U.S.A. for patients aged ≥ 12 years with moderate-to-
severe atopic dermatitis (AD) uncontrolled by topical prescription medicines or who
cannot use topical medicines, for patients in Japan whose AD is uncontrolled with
existing therapies, for patients with moderate-to-severe AD in Europe who are candi-
dates for systemic therapy and for patients aged ≥ 12 years for maintenance treatment
of moderate-to-severe asthma uncontrolled with their current medicines. AD trials
have reported increased incidence of conjunctivitis for dupilumab vs. placebo.
Objectives To characterize further the occurrence and risk factors of conjunctivitis
in dupilumab clinical trials.
Methods We evaluated randomized placebo-controlled trials of dupilumab in AD
(n = 2629), asthma (n = 2876), chronic rhinosinusitis with nasal polyps
(CRSwNP) (n = 60) and eosinophilic oesophagitis (EoE) (n = 47).
Results In most AD trials, dupilumab-treated patients had higher conjunctivitis inci-
dence than placebo controls. Higher baseline AD severity and previous history of con-
junctivitis were associated with increased conjunctivitis incidence. Conjunctivitis was
mostly mild to moderate. Most cases recovered or resolved during the treatment per-
iod; two patients permanently discontinued dupilumab due to conjunctivitis or ker-
atitis. Common treatments included ophthalmic corticosteroids, antibiotics, and
antihistamines or mast cell stabilizers. Most cases were diagnosed by the investigators.
In asthma and CRSwNP trials, the incidence of conjunctivitis was lower for both
dupilumab and placebo than in AD trials; dupilumab did not increase the incidence
compared with placebo. In the EoE trial, no patients had conjunctivitis.
Conclusions Conjunctivitis was more frequent with dupilumab treatment in most
AD trials. In dupilumab trials in other type 2 diseases, incidence of conjunctivitis
was overall very low, and was similar for dupilumab and placebo. In AD, the
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incidence of conjunctivitis was associated with AD severity and prior history of
conjunctivitis. The aetiology and treatment of conjunctivitis in dupilumab-treated
patients require further study.
What’s already known about this topic?
• Ocular disorders, including allergic conjunctivitis, are common in patients with
atopic dermatitis (AD).
• In most dupilumab AD trials, dupilumab-treated patients had higher conjunctivitis
incidence than those receiving placebo.
• Most cases were mild to moderate and recovered or were recovering during study
treatment; study treatment discontinuation due to conjunctivitis was rare.
• Conjunctivitis incidence was very low and similar for dupilumab and placebo in
clinical trials in asthma, chronic rhinosinusitis with nasal polyps and eosinophilic
oesophagitis.
What does this study add?
• This analysis confirms and extends the results of the individual clinical trials.
• Baseline disease-related factors, including AD severity, prior conjunctivitis history
and certain biomarkers (thymus and activation-regulated chemokine, IgE, eosino-
phils), were associated with increased incidence of conjunctivitis.
• Patients who responded well to dupilumab had reduced incidence of conjunctivitis.
• Further study is needed to elucidate the aetiology and treatment of conjunctivitis in
dupilumab-treated patients with AD.
Ocular surface diseases, such as allergic conjunctivitis, blephari-
tis and keratitis, are well-known ophthalmic complications in
patients with severe atopic dermatitis (AD), with incidence rates
of 324–558%.1–8 The incidence of ophthalmic complications
increases with AD severity.4,8 Allergic conjunctivitis and other
ocular surface disorders are also common comorbidities of
other atopic disorders such as asthma and allergic rhinitis.9–17
Dupilumab is a fully human VelocImmune-derived18,19
monoclonal antibody blocking the shared receptor component
for interleukin (IL)-4 and IL-13, thus inhibiting signalling of
both IL-4 and IL-13.
Dupilumab is approved for subcutaneous administration at
300 mg every 2 weeks (q2w) for patients aged ≥ 12 years in
the U.S.A. with moderate-to-severe AD inadequately controlled
with topical prescription therapies or when those therapies are
not advisable.20 It is also approved for the treatment of adult
patients with AD not adequately controlled with existing ther-
apies in Japan, and for use in adults with inadequately con-
trolled, moderate-to-severe AD who are candidates for
systemic therapy in the European Union.21 Dupilumab is also
used as an add-on maintenance treatment in patients aged ≥
12 years with moderate-to-severe asthma and an eosinophilic
phenotype or oral corticosteroid dependence.20
In clinical trials, dupilumab demonstrated efficacy and safety
in AD,22–26 asthma,27–31 chronic rhinosinusitis with nasal
polyps (CRSwNP)32 and eosinophilic oesophagitis (EoE),33
demonstrating that IL-4 and IL-13 are key drivers of multiple
type 2 inflammatory diseases.
Ocular surface disorders, including conjunctivitis, blephari-
tis, keratitis, eye pruritus and dry eye, are commonly reported
adverse events (AEs) in dupilumab-treated patients with
AD.20,21 Conjunctivitis of all aetiologies and phenotypes with
or without eyelid or corneal involvement was dominant
among all ocular AEs reported in dupilumab clinical trials in
AD.20,21,24–26,34,35 To characterize conjunctivitis in patients
treated with dupilumab, we reviewed the results of published
clinical trials, and synthesized the available data on incidence
rates, disease course and associated baseline characteristics of
patients who developed conjunctivitis in randomized, double-
blinded, placebo-controlled trials of dupilumab in AD, asthma,
CRSwNP and EoE.
Patients and methods
Studies
Eleven randomized, double-blinded, placebo-controlled phase
II and phase III clinical trials were included in this analysis.
This included 2629 patients in six AD trials: R668-AD-1021
(NCT01859988), LIBERTY AD SOLO 1 (NCT02277743), LIB-
ERTY AD SOLO 2 (NCT02277769), LIBERTY AD CHRONOS
(NCT02260986), LIBERTY AD CAFE (NCT02755649) and
LIBERTY AD SOLO-CONTINUE (NCT02395133);23–26,36 2876
patients in three asthma trials: DRI12544 (NCT01854047),
LIBERTY ASTHMA QUEST (NCT02414854) and LIBERTY
ASTHMA VENTURE (NCT02528214);28–31 60 patients in one
© 2019 The Authors. British Journal of Dermatology
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CRSwNP trial: ACT12340 (NCT01920893)32 and 47 patients
in one EoE trial: R668-EE-1324 (NCT02379052) (Table S1;
see Supporting Information).33 Details of the study method-
ologies were previously published.23–33,36 Data were pooled
for the three AD 16-week monotherapy studies (monotherapy
pool: R668-AD-1021, SOLO 1 and SOLO 2).
All trials were conducted in accordance with the ethical
principles that have their origin in the Declaration of Helsinki
and are consistent with the International Council for Harmoni-
sation guidelines for good clinical practice and applicable reg-
ulatory requirements.23–33,36
End points and assessments
Clinical trial investigators (mostly dermatologists or allergists)
diagnosed and reported conjunctivitis AEs, which were subse-
quently coded using Medical Dictionary for Regulatory Activi-
ties (MedDRA) preferred terms (PTs). Unless otherwise
specified, the term ‘conjunctivitis’ refers to the group of PTs
that included the term ‘conjunctivitis’, namely conjunctivitis,
allergic conjunctivitis, bacterial conjunctivitis, viral conjunc-
tivitis, adenoviral conjunctivitis and atopic keratoconjunctivitis.
All cases of conjunctivitis were included regardless of aetiol-
ogy (including blepharoconjunctivitis, which was coded as the
MedDRA PT conjunctivitis; and excluding blepharitis in the
absence of conjunctivitis).
The study protocols did not require any specific query about
ocular symptoms. AEs were generally reported by patients spon-
taneously, in response to the query ‘did you have any prob-
lems?’, or by investigators on physical examination during
clinical visits. Investigators who reported conjunctivitis of
unspecified aetiology were asked for more details, and whether
they could use a more specific PT. In most cases, the aetiology
remained unspecified or was designated ‘allergic’ by the investi-
gator. Investigators differed in how they categorized conjunctivi-
tis to type, as there were no prespecified classification guidelines.
Most cases reported as infectious (e.g. viral or bacterial) did not
have laboratory confirmation of infectious aetiology. Most cases
were not referred to ophthalmologists or other eye specialists.
The impact of baseline demographic and disease characteris-
tics; baseline serum levels of thymus and activation-regulated
chemokine (TARC; CCL17), IgE and blood eosinophil counts;
and efficacy responses on conjunctivitis incidence rates were
summarized for the monotherapy pool, CHRONOS and CAFE.
We evaluated the relationship between dupilumab concentra-
tion and conjunctivitis in pooled data from SOLO 1, SOLO 2
and CHRONOS.
Statistical analytical methods
These analyses evaluated all patients who received at least one
dose of study drug by treatment and dose regimen received.
Incidence rates described proportions of patients with at least
one conjunctivitis event, without modelling or censoring for
patient withdrawal or rescue medication use. Hazard ratios
(HRs) and 95% confidence intervals (CIs) were estimated
based on a Cox regression model (with censoring after
patients’ withdrawal), to describe the relative risk for time to
first conjunctivitis event, comparing the dupilumab and pla-
cebo groups. Treatment groups were fixed effects and the
analysis was stratified by study and baseline disease severity
[Investigator’s Global Assessment (IGA) = 3 vs. 4 for AD-
1021, SOLO, CHRONOS and CAFE; or IGA = 0 vs. 1 vs. 2 for
SOLO-CONTINUE]. Medians, percentiles and 95% CIs were
obtained from Kaplan–Meier estimates.
Relationships of baseline characteristics and treatment response
with conjunctivitis incidence were evaluated using descriptive
statistics. Results from post hoc analyses showing annualized rate
ratios by various factors were extracted from a duration-adjusted
Poisson model. Relationships between dupilumab concentration
and conjunctivitis incidence were evaluated by dupilumab con-
centration (observed Ctrough, predicted Ctrough and AUCtau) in the
placebo and dupilumab groups, based on pooled data from
SOLO 1, SOLO 2 and CHRONOS, for weeks 0–16.
Results
Atopic dermatitis clinical trials
Incidence of conjunctivitis
The incidence and HR of treatment-emergent conjunctivitis
were higher in dupilumab-treated vs. placebo-treated patients
in the monotherapy pool, CHRONOS and CAFE. In the
monotherapy pool, incidence rates (HR) for dupilumab vs. pla-
cebo after 16 weeks of treatment were 86% vs. 21% (HR
413, 95% CI 221–772) (Table 1). A similar pattern was seen
when adjusting for patient exposure [2998 vs. 729 patients,
respectively, per 100 patient-years (PY)] (Table S2; see Sup-
porting Information). In CHRONOS, incidence rates (HR) for
dupilumab + topical corticosteroids (TCS) vs. placebo + TCS
over the 52-week treatment period were 179% vs. 79%,
respectively (HR 231, 95% CI 147–363) (Table 2). When
adjusting for exposure, the rates were 2144 vs. 924 patients
per 100 PY, respectively (Table S2; see Supporting Informa-
tion). The highest conjunctivitis rates were reported in CAFE,
with incidence rates for dupilumab + TCS vs. placebo + TCS
over the 16-week treatment period of 221% vs. 111%,
respectively (HR 206, 95% CI 109–388) (Table 3). Dura-
tion-adjusted rates were 8113 vs. 3894 patients per 100 PY,
respectively (Table S2; see Supporting Information).
In SOLO-CONTINUE, patients who responded well to dupi-
lumab in either SOLO 1 or SOLO 2 were rerandomized to 36
weeks of treatment at their original dose regimen or longer-
interval regimens (every 4 weeks, q4w; or every 8 weeks,
q8w) or placebo. In contrast to the other AD trials, in SOLO-
CONTINUE there was no apparent difference in conjunctivitis
incidence and HR between dupilumab and placebo (47% vs.
4.9%; HR 100, 95% CI 033–298; 725 vs. 745 patients per
100 PY) (Table 4 and Table S2; see Supporting Information).
In the monotherapy pool, CHRONOS and SOLO-CON-
TINUE, conjunctivitis incidence rates were similar across
© 2019 The Authors. British Journal of Dermatology
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dupilumab dose regimens within each study. In CAFE, inci-
dence rates were numerically lower for dupilumab 300 mg
qw + TCS than for 300 mg q2w + TCS (Table 3).
Conjunctivitis severity, treatment and resolution
Conjunctivitis AEs were mostly mild to moderate. Severe con-
junctivitis was reported in ≤ 05% of dupilumab-treated
(dupilumab combined) and ≤ 03% of placebo-treated patients
(Fig. 1). One patient in the 300-mg qw group in the
monotherapy pool permanently discontinued the study drug
due to conjunctivitis, and one patient in the 300-mg qw +
TCS group in CHRONOS permanently discontinued the study
drug due to allergic keratitis (MedDRA PT; the verbatim term
was ‘worsening of allergic keratoconjunctivitis’).
Most cases were resolved or resolving by the end of the
treatment period (Tables 5–8). The most common treatments
were ophthalmic preparations of corticosteroids, antibiotics,
and antihistamines or mast cell stabilizers. The proportion of
patients who required continued or intermittent ongoing ther-
apy for conjunctivitis could not be determined with the avail-
able data.
Onset of conjunctivitis
Numerical differences between placebo and dupilumab in new
conjunctivitis events were apparent after week 2 in the
monotherapy pool, after about weeks 6–8 in CHRONOS and
after about weeks 4–8 in CAFE (Fig. 2). For the monotherapy
pool and CAFE, new conjunctivitis events appeared at a
Table 1 Proportion of patients with at least one adverse event of conjunctivitis during the treatment period in atopic dermatitis trials, and hazard
ratios (HRs) with 95% confidence intervals (CIs) for dupilumab vs. placebo: monotherapy pool
MedDRA preferred term
Patients with ≥ 1 event: n (%) and HR vs. placebo (95% CI)
Placebo
(n = 517)
Dupilumab 300 mg q2w
(n = 529)
Dupilumab 300 mg qw
(n = 518)
Dupilumab combined
(n = 1047)
Total 11 (21) 49 (93) 41 (79) 90 (86)
443 (230–851) 380 (195–740) 413 (221–772)
Conjunctivitis 3 (06) 21 (40) 20 (39) 41 (39)
684 (204–229) 669 (199–225) 677 (210–219)
Allergic conjunctivitis 5 (10) 16 (30) 12 (23) 28 (27)
305 (112–834) 238 (084–675) 275 (106–712)
Bacterial conjunctivitis 2 (04) 7 (13) 8 (15) 15 (14)
337 (070–162) 394 (084–186) 364 (083–159)
Viral conjunctivitis 1 (02) 4 (08) 1 (02) 5 (05)
390 (044–349) 100 (006–159) 244 (028–209)
Atopic keratoconjunctivitis 0 1 (02) 1 (02) 2 (02)
296 9 107 (000–NC) 277 9 107 (000–NC) 170 9 107 (000–NC)
The HR and its 95% CI are from a Cox regression model, which includes treatment groups as fixed effects, stratified by study identifier and
baseline disease severity (Investigator’s Global Assessment = 3 vs. 4). MedDRA, Medical Dictionary for Regulatory Activities; q2w, every 2
weeks; qw, every week; NC, not calculable.
Table 2 Proportion of patients with at least one adverse event of conjunctivitis during the treatment period in atopic dermatitis trials, and hazard
ratios (HRs) with 95% confidence intervals (CIs) for dupilumab vs. placebo: CHRONOS
MedDRA preferred term
Patients with ≥ 1 event: n (%) and HR vs. placebo (95% CI)
Placebo + TCS
(n = 315)
Dupilumab 300 mg q2w + TCS
(n = 110)
Dupilumab 300 mg qw + TCS
(n = 315)
Dupilumab + TCS combined
(n = 425)
Total 25 (79) 15 (136) 61 (194) 76 (179)
176 (093–333) 251 (157–399) 231 (147–363)
Allergic conjunctivitis 15 (48) 12 (109) 47 (149) 59 (139)
233 (109–498) 316 (177–566) 295 (167–520)
Bacterial conjunctivitis 5 (16) 2 (18) 9 (29) 11 (26)
111 (022–575) 176 (059–527) 160 (055–459)
Conjunctivitis 5 (16) 1 (09) 8 (25) 9 (21)
056 (007–479) 156 (051–476) 130 (043–387)
Atopic keratoconjunctivitis 1 (03) 0 2 (06) 2 (05)
0 (0–NC) 192 (017–211) 142 (013–157)
The HR and its 95% CI are from a Cox regression model, which includes treatment groups as fixed effects, stratified by baseline disease
severity (Investigator’s Global Assessment = 3 vs. 4). MedDRA, Medical Dictionary for Regulatory Activities; q2w, every 2 weeks; qw, every
week; NC, not calculable; TCS, topical corticosteroids.
© 2019 The Authors. British Journal of Dermatology
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relatively constant rate throughout the 16-week studies
(Fig. 2a,c). In CHRONOS, new cases appeared to level off
around weeks 20–24 and were relatively uncommon after week
44 (Fig. 2b). The mean time to the first event was similar
between dupilumab dose regimens in these studies (Fig. 2).
Baseline characteristics of patients with and without
conjunctivitis
Patients who reported conjunctivitis during the treatment per-
iod had more severe AD at baseline than patients who did not
report conjunctivitis, regardless of assigned treatment group
(dupilumab or placebo) (Fig. 3 and Table S3; see Supporting
Information). In addition, prior history of conjunctivitis
(Fig. 4 and Table S3), as well as higher baseline levels of the
serum biomarkers TARC and IgE and higher baseline
circulating eosinophil counts (all suggestive of higher disease
severity), were associated with conjunctivitis in both dupilu-
mab- and placebo-treated patients (Figs S1 and S2 and
Table S3).
Conjunctivitis and response to dupilumab
The relationship between treatment response and conjunctivi-
tis incidence varied between treatment groups and studies.
Patients who achieved high-level efficacy outcomes [IGA 0/1
or ≥ 75% improvement from baseline Eczema Area and Sever-
ity Index (EASI 75)] in the monotherapy pool were less likely
to develop conjunctivitis than those who did not achieve those
outcomes. In CHRONOS and CAFE, this pattern was apparent
only in the dupilumab q2w and placebo groups (Figs S3 and
S4; see Supporting Information).
Table 3 Proportion of patients with at least one adverse event of conjunctivitis during the treatment period in atopic dermatitis trials, and hazard
ratios (HRs) with 95% confidence intervals (CIs) for dupilumab vs. placebo: CAFE
MedDRA preferred term
Patients with ≥ 1 event: n (%) and HR vs. placebo (95% CI)
Placebo + TCS
(n = 108)
Dupilumab 300 mg q2w + TCS
(n = 107)
Dupilumab 300 mg qw + TCS
(n = 110)
Dupilumab + TCS combined
(n = 217)
Total 12 (111) 30 (280) 18 (164) 48 (221)
269 (138–526) 147 (071–306) 206 (109–388)
Allergic conjunctivitis 7 (65) 16 (150) 10 (91) 26 (120)
234 (096–568) 140 (053–368) 187 (081–430)
Conjunctivitis 3 (28) 12 (112) 8 (73) 20 (92)
428 (121–152) 270 (071–102) 344 (102–11.56)
Bacterial conjunctivitis 2 (19) 1 (09) 0 1 (05)
050 (005–557) 0 (0–NC) 025 (002–277)
Viral conjunctivitis 1 (09) 1 (09) 0 1 (05)
099 (006–158) 0 (0–NC) 049 (003–788)
Adenoviral conjunctivitis 0 1 (09) 0 1 (05)
30 9 107 (000–NC) 0 (0–NC) 17 9 107 (000–NC)
The HR and its 95% CI are from a Cox regression model, which includes treatment groups as fixed effects, stratified by baseline disease
severity (Investigator’s Global Assessment = 3 vs. 4). MedDRA, Medical Dictionary for Regulatory Activities; q2w, every 2 weeks; qw, every
week; NC, not calculable; TCS, topical corticosteroids.
Table 4 Proportion of patients with at least one adverse event of conjunctivitis during the treatment period in atopic dermatitis trials, and hazard
ratios (HRs) with 95% confidence intervals (CIs) for dupilumab vs. placebo: SOLO-CONTINUE
MedDRA preferred term
Patients with ≥ 1 event: n (%) and HR vs. placebo (95% CI)
Placebo
(n = 82)
Dupilumab 300 mg q8w
(n = 84)
Dupilumab 300 mg q4w
(n = 87)
Dupilumab 300 mg qw
or q2w (n = 167)
Dupilumab combined
(n = 338)
Total 4 (4.9) 3 (3.6) 4 (4.6) 9 (54) 16 (47)
075 (017–336) 100 (025–399) 113 (035–368) 100 (033–298)
Conjunctivitis 2 (2.4) 2 (2.4) 2 (2.3) 6 (36) 10 (30)
100 (014–710) 099 (014–700) 151 (030–746) 124 (027–565)
Allergic conjunctivitis 1 (1.2) 1 (1.2) 2 (2.3) 2 (12) 5 (15)
105 (007–1685) 205 (019–227) 102 (009–112) 126 (015–108)
Bacterial conjunctivitis 1 (1.2) 0 0 1 (06) 1 (03)
0 (0–NC) 0 (0–NC) 048 (003–764) 024 (002–390)
The HR and its 95% CI are from a Cox regression model, which includes treatment groups as fixed effects, stratified by baseline disease
severity (Investigator’s Global Assessment = 3 vs. 4). MedDRA, Medical Dictionary for Regulatory Activities; q8w, every 8 weeks; q4w, every
4 weeks; q2w, every 2 weeks; qw, every week; NC, not calculable.
© 2019 The Authors. British Journal of Dermatology
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Dupilumab exposure and conjunctivitis
Pooled data from baseline to week 16 in SOLO 1 and 2 and
CHRONOS showed a trend suggesting that conjunctivitis inci-
dence may decrease with higher trough concentrations of
dupilumab (Table S4; see Supporting Information).
Asthma, chronic rhinosinusitis with nasal polyps and
eosinophilic oesophagitis
In all asthma trials, incidence rates of conjunctivitis were low,
with no apparent differences between dupilumab- and pla-
cebo-treated patients (Tables 9–11). In DRI12544, seven of
611 (11%) dupilumab-treated and two of 158 (13%) pla-
cebo-treated patients developed conjunctivitis. In QUEST, 22
of 1263 (17%) dupilumab-treated and 15 of 634 (24%) pla-
cebo-treated patients developed conjunctivitis. In VENTURE,
only one of 103 (10%) dupilumab-treated and one of 107
(09%) placebo-treated patients developed conjunctivitis
(Tables 9–11).
In the CRSwNP trial, no dupilumab-treated patients and one
of 30 (3%) placebo-treated patients developed conjunctivi-
tis (Table 12). In the EoE trial, no patients developed conjunc-
tivitis.
In all of these trials, all cases were mild or moderate
(Fig. S5; see Supporting Information), and nearly all patients
recovered by the end of the treatment period (Table S5).
Discussion
This analysis confirmed that patients with AD treated with
dupilumab had a greater incidence of conjunctivitis (86–
221%) than placebo-treated patients (21–111%) in most of
the randomized, placebo-controlled AD clinical trials included
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in this analysis, except for SOLO-CONTINUE.23–26,36 This is
consistent with the higher rates of external eye disorders,
including conjunctivitis, blepharitis, keratitis, eye pruritus and
dry eye, described for patients with AD in the dupilumab pre-
scribing information.20,21 Patients with AD were more likely
to develop conjunctivitis if they had higher baseline AD
Table 5 Resolution of conjunctivitis events during the treatment period: monotherapy pool
Placebo qw
(n = 517)
Dupilumab 300 mg q2w
(n = 529)
Dupilumab 300 mg qw
(n = 518)
Dupilumab combined
(n = 1047)
Overall number of conjunctivitis events 12 57 46 103
Recovered/resolved 11 (92, 62–100) 35 (61, 48–74) 32 (70, 54–82) 67 (65, 55–74)
Not recovered/resolved 1 (8, 0–38) 14 (25, 14–38) 6 (13, 5–26) 20 (19, 12–28)
Recovered/resolved with sequelae 0 0 1 (2, 0–12) 1 (1, 0–5)
Recovering/resolving 0 7 (12, 5–24) 6 (13, 5–26) 13 (13, 7–21)
Unknown 0 1 (2, 0–9) 1 (2, 0–12) 2 (2, 0–7)
Data are resolution of events, presented as n [%, 95% confidence interval (CI)]. CIs are generated from the exact or Clopper–Pearson method.
qw, every week; q2w, every 2 weeks.
Table 6 Resolution of conjunctivitis events during the treatment period: CHRONOS
Placebo + TCS
(n = 315)
Dupilumab 300 mg
q2w + TCS (n = 110)
Dupilumab 300 mg
qw + TCS (n = 315)
Dupilumab + TCS
combined (n = 425)
Overall number of conjunctivitis events 29 23 91 114
Recovered/resolved 27 (93, 77–99) 18 (78, 56–93) 81 (89, 81–95) 99 (87, 79–92)
Not recovered/resolved 1 (3, 0–18) 3 (13, 3–34) 7 (8, 3–15) 10 (9, 4–16)
Recovered/resolved with sequelae 0 0 1 (1, 0–6) 1 (1, 0–5)
Recovering/resolving 1 (3, 0–18) 2 (9, 1–28) 2 (2, 0–8) 4 (4, 1–9)
Data are resolution of events, presented as n [%, 95% confidence interval (CI)]. CIs are generated from the exact or Clopper–Pearson method.
TCS, topical corticosteroids; q2w, every 2 weeks; qw, every week.
Table 7 Resolution of conjunctivitis events during the treatment period: CAFE
Placebo + TCS
(n = 108)
Dupilumab 300 mg
q2w + TCS (n = 107)
Dupilumab 300 mg
qw + TCS (n = 110)
Dupilumab + TCS
combined (n = 217)
Overall number of conjunctivitis events 15 37 19 56
Recovered/resolved 11 (73, 45–92) 14 (38, 22–55) 15 (79, 54–94) 29 (52, 38–65)
Not recovered/resolved 2 (13, 2–40) 13 (35, 20–53) 2 (11, 1–33) 15 (27, 16–40)
Recovered/resolved with sequelae 1 (7, 0–32) 1 (3, 0–14) 0 1 (2, 0–10)
Recovering/resolving 1 (7, 0–32) 8 (22, 10–38) 2 (11, 1–33) 10 (18, 9–30)
Unknown 0 1 (3, 0–14) 0 1 (2, 0–10)
Data are resolution of events, presented as n [%, 95% confidence interval (CI)]. CIs are generated from the exact or Clopper–Pearson method.
TCS, topical corticosteroids; q2w, every 2 weeks; qw, every week.
Table 8 Resolution of conjunctivitis events during the treatment period: SOLO-CONTINUE
Placebo
(n = 82)
Dupilumab 300 mg
q8w (n = 84)
Dupilumab 300 mg
q4w (n = 87)
Dupilumab 300 mg qw
or q2w (n = 167)
Dupilumab
combined
(n = 338)
Overall number of conjunctivitis events 4 5 4 11 20
Recovered/resolved 4 (100) 4 (80, 28–99) 2 (50, 7–93) 9 (82, 48–98) 15 (75, 51–91)
Not recovered/resolved 0 1 (20, 1–72) 2 (50, 7–93) 1 (9, 0–41) 4 (20, 6–44)
Recovered/resolved with sequelae 0 0 0 0 0
Recovering/resolving 0 0 0 1 (9, 0–41) 1 (5, 0–25)
Data are resolution of events, presented as n [%, 95% confidence interval (CI)]. CIs are generated from the exact or Clopper–Pearson method.
q8w, every 8 weeks; q4w, every 4 weeks; q2w, every 2 weeks; qw, every week.
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severity, high levels of certain biomarkers or self-reported his-
tory of conjunctivitis. By contrast, randomized, placebo-con-
trolled clinical trials of dupilumab in asthma, CRSwNP and
EoE had low and similar incidence rates of conjunctivitis in
dupilumab- (0–17%) and placebo-treated (0–33%)
patients.28–33 In all trials, most cases of conjunctivitis were
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mild or moderate, and most resolved while continuing dupi-
lumab treatment.
Multiple factors (disease based and treatment based) are
associated with incidence of conjunctivitis in these studies.
Baseline AD severity and prior conjunctivitis history are most
likely independent risk factors for conjunctivitis irrespectively
of treatment, as incidence increases with baseline severity
and prior history in placebo-treated patients (as well as in
dupilumab-treated patients). CAFE, which had both the
highest baseline level of AD severity and the highest rates of
prior conjunctivitis history among all the AD trials, also had
the highest rates of conjunctivitis. CAFE was a later trial in
this series, in which there might have been higher aware-
ness of conjunctivitis as a potential AE. In contrast, conjunc-
tivitis rates were lowest in SOLO-CONTINUE, in which
high-level responders to dupilumab from SOLO 1 and SOLO
2 were rerandomized to continued dupilumab treatment or
placebo.
Levels of certain biomarkers (TARC, IgE and eosinophils)
increase with AD severity;22,37,38 thus, it is not surprising that
both baseline AD severity and increased biomarker levels were
associated with increased conjunctivitis incidence in these
studies. AD severity has been associated with increased inci-
dence of conjunctivitis,3,8 and IgE levels are increased in
patients with both AD and ocular complications.3,4
High-level efficacy responses (IGA 0/1, EASI 75) showed
an apparent association with lower conjunctivitis incidence
in dupilumab-treated patients in the monotherapy pool;
however, this trend was inconsistent or reversed in
CHRONOS and CAFE. Fewer patients with severe AD at base-
line achieved IGA 0/1 and EASI 75. Increased disease severity
is associated with higher incidence of comorbidities and
higher AD biomarkers, so these predictors may be interre-
lated.
The pharmacokinetic data suggested, somewhat paradoxi-
cally, that lower dupilumab exposure might be associated with
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increased incidence of conjunctivitis compared with higher
dupilumab exposure. This finding would not be expected if
there was a positive dose–response relationship between dupi-
lumab exposure and occurrence of conjunctivitis.
Furthermore, 80% of cases resolved while continuing on
dupilumab treatment. Thus, further study is warranted to
understand better the underlying cause of the imbalance in
events between treatment groups.
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Fig 4. Baseline characteristics and annualized events rate for patients’ first events of conjunctivitis (event rate per 100 patient-years; PY) for
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Table 9 Incidence of conjunctivitis in asthma: phase IIb (DRI12544)
Placebo
(n = 158)
Dupilumab
200 mg q4w
(n = 150)
300 mg q4w
(n = 157)
200 mg q2w
(n = 148)
300 mg q2w
(n = 156)
Combined
(n = 611)
Patients with ≥ 1 event, n (%) 2 (13) 3 (20) 2 (13) 2 (14) 0 7 (11)
Conjunctivitisa 1 (06) 3 (20) 1 (06) 1 (07) 0 5 (08)
Allergic conjunctivitisa 1 (06) 0 1 (06) 1 (07) 0 2 (03)
q4w, every 4 weeks; q2w, every 2 weeks. aMedical Dictionary for Regulatory Activities preferred terms.
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Currently, there is no consensus on optimal approaches to
prevent and manage conjunctivitis in dupilumab-treated
patients. Ophthalmic preparations of corticosteroids, antibi-
otics, and antihistamines and mast cell stabilizers were the
most common treatments used for conjunctivitis in these tri-
als. Case series and case reports have described several thera-
peutic approaches used successfully in clinical practice for
treatment of conjunctivitis associated with dupilumab without
discontinuation of dupilumab, including hyaluronic acid eye-
drops, topical tacrolimus, TCS (e.g. fluorometholone, dexam-
ethasone, hydrocortisone), artificial tears, compounded oily
ciclosporin eyedrops and antibiotic–TCS combination thera-
pies.39–45 As long-term treatment with ophthalmic TCS can
lead to more serious eye disorders such as cataracts and glau-
coma, products with poor penetration into the anterior cham-
ber of the eye (e.g. fluorometholone) should be considered.
In addition, topical preparations of calcineurin inhibitors
appear to be a reasonable long-term therapeutic alternative.39
Patients who develop ocular symptoms during dupilumab
treatment should receive full ophthalmic evaluations, and
addition of an ophthalmologist to the patient management
team may be of benefit.4,39,46
An important aspect of these analyses is that, based on
existing data, and in the absence of ophthalmological or
microbiological evaluation, it was not possible to identify
events that were specific or pathognomonic for dupilumab vs.
placebo, or to confirm whether the events were infectious,
allergic or idiopathic. Data on specific clinical features of ocu-
lar AEs were not collected in these trials, and inconsistencies
in how MedDRA PTs were assigned limit the utility of com-
parison of conjunctivitis PTs between dupilumab and placebo.
Case reports have described common features of conjunctivitis
in dupilumab-treated patients from clinical practice, including
conjunctival redness, hyperaemia, blepharitis, dryness, irrita-
tion, discharge, itch, stinging, burning, tearing, foreign-body
sensation, occasional decrease in bilateral visual acuity and
ectropion.39–45 Further study into the clinical characteristics of
conjunctivitis associated with dupilumab is warranted, and
ongoing.
The exact pathogenesis of conjunctivitis events observed
during dupilumab treatment is unknown. Ocular comorbidi-
ties have high prevalence in patients with AD compared with
the overall population.1–4,47 Thus, it is possible that pre-exist-
ing ocular disorders and a dupilumab–AD disease-specific
interaction may be responsible for this increased incidence in
dupilumab-treated patients with AD, particularly as conjunc-
tivitis was not associated with dupilumab in trials in other
type 2 diseases.28–33 Allergic conjunctivitis is a common
comorbidity in asthma and allergic rhinitis, as well as in
AD.1–4,9–17,47–49 Both lesional and nonlesional skin in AD are
characterized by epithelial barrier dysfunction, including
abnormalities in keratinocyte terminal differentiation, ker-
atinocyte lipid production and tight junctions, which all con-
tribute to increased transepidermal water loss.50–52 Ocular
surface epithelia have impaired barrier function in patients
with AD.53 Although barrier dysfunction is also observed in
affected mucosal barrier tissues of other type 2 indications,
patients with AD more frequently have ocular disease. If bar-
rier abnormalities in AD differentially affect conjunctival tis-
sues compared with other type 2 diseases, this could in part
explain the differences in conjunctivitis incidence rates
between AD trials and trials of other type 2 diseases.
Table 10 Incidence of conjunctivitis in asthma: LIBERTY ASTHMA QUEST
Combined
Placebo 114 mL
(n = 313)
Dupilumab, 200 mg
q2w (n = 631)
Placebo 2 mL
(n = 321)
Dupilumab, 300 mg
q2w (n = 632)
Placebo
(n = 634)
Dupilumab
(n = 1263)
Patients with ≥ 1 event, n (%) 6 (19) 8 (13) 9 (28) 14 (22) 15 (24) 22 (17)
Conjunctivitisa 1 (03) 2 (03) 4 (12) 4 (06) 5 (08) 6 (05)
Allergic conjunctivitisa 4 (13) 5 (08) 4 (12) 8 (13) 8 (13) 13 (10)
Viral conjunctivitisa 1 (03) 1 (02) 0 2 (03) 1 (02) 3 (02)
Bacterial conjunctivitisa 0 0 1 (03) 0 1 (02) 0
q2w, every 2 weeks. aMedical Dictionary for Regulatory Activities preferred terms.
Table 11 Incidence of conjunctivitis in asthma: LIBERTY ASTHMA
VENTURE
Placebo
(n = 107)
Dupilumab 300 mg
q2w (n = 103)
Patients with ≥ 1 event, n (%) 1 (09) 1 (10)
Conjunctivitisa 0 1 (10)
Allergic conjunctivitisa 1 (09) 0
q2w, every 2 weeks. aMedical Dictionary for Regulatory Activi-
ties preferred terms.
Table 12 Incidence of conjunctivitis: chronic rhinosinusitis with nasal
polyps (ACT12340)
Placebo
(n = 30)
Dupilumab 300 mg
qw (n = 30)
Patients with ≥ 1 event, n (%) 1 (33) 0
Conjunctivitisa 1 (33) 0
qw, every week. aMedical Dictionary for Regulatory Activities
preferred terms.
© 2019 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2019)
Conjunctivitis in dupilumab clinical trials, B. Akinlade et al. 11
Several hypotheses have been proposed for mechanisms
driving conjunctivitis in dupilumab-treated patients with AD,
including alterations in cytokine activity leading to (variously)
increased Demodex mites, increased OX40 ligand activity,
eosinophilia, disruption of an immune-mediated response of
conjunctival-associated lymphoid tissue, decreased IL-13-
related mucus production and decreased IL-13-related scarcity
of conjunctival goblet cells; it is possible that multiple mecha-
nisms may be in effect.40,43,54–59 In addition, different mecha-
nisms may affect the development of conjunctivitis in
dupilumab-treated patients with AD vs. those with asthma or
other type 2 diseases. Further investigation is needed, includ-
ing collection of ocular samples, to characterize the molecular,
cellular and inflammatory changes in the eye during these
events, as well as during and after recovery or resolution.
There are several limitations to this analysis. Firstly, there
was no prespecified ocular assessment in these trials; patients
were not examined by ophthalmologists at enrolment or dur-
ing the trials. Thus, overall changes from baseline and/or
objective differentiation of changes in ocular symptoms over
time could not be determined. Secondly, conjunctivitis AEs
were reported by the trial investigators (typically dermatolo-
gists or allergists). Patients were usually not referred to oph-
thalmologists, and few AEs reported as viral or bacterial
conjunctivitis had microbiological confirmation. Nonetheless,
within the limits of diagnostic accuracy of the investigators,
the data show that dupilumab-treated patients had higher rates
of conjunctivitis. Thirdly, there are limitations related to classi-
fication of AEs by MedDRA. Lower-level terms with higher
specificity are very numerous (> 100), so the analysis had to
be done at the PT level; for example, the lower-level terms of
‘blepharoconjunctivitis’ would default to the PT of conjunc-
tivitis. For the purpose of signal detection, it was necessary to
cluster multiple PTs to avoid this fragmentation. In addition,
during AE coding, the MedDRA PTs of ‘conjunctivitis’ and
‘conjunctivitis allergic’ were sometimes used interchangeably;
therefore, these two terms should be considered equivalent.
MedDRA coding of conjunctivitis AEs may result in classifica-
tion of these events as either the MedDRA system organ class
of ‘eye disorders’ or as ‘infections and infestations’, depending
on the verbatim report of the investigator. Fourthly, history of
conjunctivitis was self-reported by patients, with likelihood of
recall bias, as different symptoms from patients’ history could
be misinterpreted by the patients and/or investigators as con-
junctivitis. Fifthly, the increasing incidence of conjunctivitis
reported in the placebo groups of the different AD trials over
time suggests that both an ‘awareness bias’ of the trial investi-
gators in the later AD trials and a possible initial underdiagno-
sis of conjunctivitis in earlier trials may have influenced
apparent increases in reported incidences of dupilumab-asso-
ciated conjunctivitis across studies over time. Finally, conclu-
sions on the incidence of conjunctivitis in CRSwNP and EoE
are limited by the small number of patients in the proof-of-
concept trials included in this analysis.32,33 These indications
are still in development; future analyses will incorporate data
from larger ongoing and future studies.
In conclusion, the higher incidence of conjunctivitis in dupi-
lumab-treated patients with AD appears to be associated with
several disease-based factors, including baseline AD severity and
previous history of conjunctivitis. Dupilumab treatment was not
associated with increased incidence of conjunctivitis in asthma,
CRSwNP and EoE trials. In most cases, conjunctivitis AEs were
mild to moderate. Most cases resolved or were resolving while
patients continued their dupilumab treatment, but the data do
not allow for determination of the proportion of patients who
required continued or intermittent ongoing therapy for con-
junctivitis. For timely appropriate intervention, we recommend
referral for a detailed eye examination in patients who develop
this complication while on dupilumab treatment. Further stud-
ies, including mechanistic investigations of ocular or conjuncti-
val samples, are needed to characterize clinical phenotypes and
understand the aetiology of the observed conjunctivitis AEs in
the setting of dupilumab treatment, and to develop guidance
for prevention and management.
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